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Background. Guidelines recommend intravenous thrombolysis to be applied as early 1 
as possible in ischemic stroke, while clinical presentation is often assessed by using 2 
the National Institutes of Health Stroke Scale (NIHSS). However, diagnostic work-up 3 
under time pressure bears the risk of misdiagnosis. Little is known whether NIHSS 4 
could help to differentiate between ischemic stroke and stroke mimics in patients being 5 
evaluated for intravenous thrombolysis. 6 
 7 
Methods. Prospectively collected data of 326 consecutive patients treated with 8 
intravenous thrombolysis were analyzed. Baseline characteristics and NIHSS 9 
subscores were compared between stroke mimics and ischemic strokes.  10 
 11 
Results. Of 326 patients, 23 (7%) had a final diagnosis other than ischemic stroke. Age 12 
and vascular risk factors were comparable in both groups. Patients with stroke mimics 13 
less often had oculomotor disturbance (0% vs. 37%, p<0.001), dysarthria (9% vs. 51%, 14 
p<0.001), hemineglect (0% vs. 30%, p<0.01), hemianopia (0% vs. 22%, p<0.01) and 15 
facial palsy (33% vs. 70%, p<0.01). On the other hand, global aphasia without 16 
hemiparesis was more prevalent in stroke mimics (43% vs. 6%, p<0.001).  17 
 18 
Conclusion.  Our study suggests that patients with stroke mimics undergoing intravenous 19 
thrombolysis present with a different pattern of clinical deficits as compared to those with 20 
ischemic stroke. 21 
 22 
 23 
 24 
 25 
 26 
 2  
INTRODUCTION 1 
Patients presenting with an acute onset of neurological symptoms need to be quickly 2 
evaluated, because they may have a stroke for which immediate treatment is 3 
mandatory. Intravenous thrombolysis (IVT) can only be delivered within 4.5 hours of 4 
symptom onset with the likehood of good outcome decreasing with time to treatment 5 
[1]. Therefore, history and examination remain short and focused in the emergency 6 
setting, while clinical stroke severity is often assessed by using the National Institutes 7 
of Health Stroke Scale (NIHSS) [2]. Acute brain imaging is often restricted to computed 8 
tomography (CT) which can exclude intracranial hemorrhage, but in most cases cannot 9 
prove ischemia. These constraints pose the risk of misdiagnosis and administering IVT 10 
to patients who present with symptoms suggestive of ischemic stroke (IS) but finally 11 
have a different diagnosis at discharge (so-called “stroke mimic”, SM). It has not been 12 
evaluated whether patients with SM differ from those with IS in NIHSS subscores that 13 
could help physicians to suspect SM clinically. Furthermore, little is known about 14 
frequency of stroke mimics (SM) in the extended 4.5h treatment time window. We 15 
aimed to assess the frequency, clinical characteristics and the risk for adverse events 16 
in SM patients treated with IVT within 4.5 hours after symptom onset. 17 
 18 
 19 
PATIENTS AND METHODS 20 
We analyzed data collected prospectively as part of the Zurich Observational Registry 21 
of Rehabilitation Outcomes (ZORRO). 326 consecutive patients who were treated with 22 
intravenous r-tPA in the University Hospital Zurich from October 2008 to May 2011 23 
were included. SM was diagnosed when all of the following 3 criteria were met: 1.) 24 
clinical condition at admission suggesting acute ischemic stroke, 2.) normal diffusion-25 
weighted magnetic resonance imaging (MRI) of brain, and 3.) specific diagnosis at 26 
 3  
discharge other than ischemic stroke. The specific diagnosis was based on clinical 1 
course and additional investigations if needed (e.g. characteristic findings in 2 
electroencephalography; history of migraine, epilepsy or conversion disorder; specific 3 
laboratory or imaging findings). Patients with normal diffusion-weighted MRI but unclear 4 
diagnosis at hospital discharge were excluded as were patients with clinically probable 5 
stroke or transient ischemic attack and normal MRI. Normal neuroimaging in the setting 6 
of unknown cause as well as probable stroke or transient ischemic attack were 7 
excluded from the definition. Baseline investigations included neurologic and physical 8 
examination, assessment of stroke severity at admission by using the NIHSS [2], 9 
routine blood analysis, 12-lead electrocardiography (ECG), and brain CT. The following 10 
variables were prospectively collected: age, gender, baseline NIHSS score, vascular 11 
risk factors according to predefined criteria [3], time to treatment and history for 12 
coronary heart disease or prior ischemic stroke, and the NIHSS subscores. 13 
Thrombolysis was applied according to current guidelines with r-tPA 0.9 mg/kg to a 14 
maximum of 90 mg, ten percent of the total dose given as a bolus and the remaining 15 
dose over the next hour [4]. Based on the results of European Cooperative Acute 16 
Stroke Study (ECASS) III, we regularly extended the time window for all IVT to 4.5 17 
hours after symptom onset from October 2008 onwards [5]. All patients treated with IVT 18 
were admitted to intermediate or intensive care units for at least 24 hours.  19 
 20 
Outcome Parameters 21 
All intracranial hemorrhages were ascertained on follow-up CT or MRI routinely 22 
performed at 24 hours after IVT and additional scans in case of clinical deterioration. 23 
Symptomatic intracranial hemorrhage (sICH) was defined as any intracranial bleed 24 
temporally related to a neurological deterioration [6]. Furthermore, we assessed the 25 
 4  
NIHSS and modified Rankin Scale (mRS) score at discharge in patients with final 1 
diagnosis of SM [2,7].  2 
 3 
Literature Search 4 
Two independent observers (A.R.G., H.S.) performed a detailed literature search in the 5 
PubMed, Embase and Cochrane databases for any reports on IVT in patients 6 
presenting with SM (search period defined from January 1995 to August 2011). First, 7 
we searched for the search terms (“stroke mimic” OR “stroke misdiagnosis”) AND 8 
(“thrombolysis”, “alteplase” OR “rtPA”). We also screened reference lists of all retrieved 9 
reports. There were no restrictions regarding language or publication status. 10 
 11 
 12 
Statistical analysis 13 
Baseline and demographic data were examined with descriptive statistics. For the 14 
comparison of the group of stroke mimics vs. ischemic stroke, the Fisher’s exact test 15 
was used for the dichotomous variables and the Wilcoxon rank sum test was used for 16 
the continuous variables. Significance was assumed at p<0.05. All tests were 17 
performed with the statistical software R 2.13 (2011).  18 
 19 
RESULTS 20 
Study population 21 
Within the study period, a total of 326 patients with suspected ischemic were treated 22 
with IVT. Of these, 23 (7%) patients (13 males, 10 females) with mean age of 63 years 23 
(range 26-86 years) presented with SM. There were no significant differences in 24 
demographic characteristics and vascular risk factors as compared to patients with IS 25 
(Table 1). Stroke severity at admission was less severe in patients with stroke mimic 26 
 5  
(NIHSS 6 vs. 10, p = 0.003) (Table 1). Furthermore, patients with SM were treated on 1 
average 52 minutes later than patients with IS (208 vs. 156 min). Table 2 shows a 2 
detailed description of clinical and imaging findings in 23 patients with SM. Before 3 
thrombolysis, 21 patients underwent neuroimaging by CT and CT angiography (CTA), 1 4 
patient (Nr.1) by CT without contrast agent and 1 patient (Nr.8) by CT, CTA and 5 
perfusion CT. All CTA and the perfusion CT were normal. MRI was performed in all 23 6 
patients with SM at 24 hours after IVT and the DWI sequences were normal in all of 7 
them. SM were most frequently diagnosed as epileptic seizures (n=14), migraine with 8 
aura (n=3) and conversion disorder (n=3). The remaining 3 patients had less frequent 9 
causes for SM: hypoglycemia (blood glucose of 2.6 mmol/l at admission), sinusitis with 10 
systemic infection and multiple sclerosis with a demyelinating lesion in the cervical 11 
spinal cord.  12 
 13 
We assessed the NIHSS subgroups in the 2 cohorts at admission. As compared to IS, 14 
no patient with SM presented with oculomotor disturbance (0% vs. 37%, p=0.0001), 15 
hemianopia (0% vs. 22%, p=0.0093) or hemineglect (0% vs. 30%, p=0.0013). 16 
Dysarthria and facial palsy was less often observed in these patients (9% vs. 51%, 17 
p=0.0003 and 33% vs. 70%, p=0.0012, respectively). Furthermore, a marginal 18 
difference was observed in the frequency of arm paresis which was slightly higher in 19 
the IS group (78% vs. 52%, p=0.0166). On the other hand, no significant differences 20 
were evident between SM and IS groups when comparing common stroke findings 21 
such as leg paresis (48% vs. 66%, p=0.0984), sensory disturbances (38% vs. 53%, 22 
p=0.252), problems in answering questions (57% vs. 34%, p=0.053) or performing 23 
tasks (24% vs. 22%, p=1.0). However, the combined occurrence of global aphasia 24 
without hemiparesis was much more frequent in the SM group (43% vs. 6%, 25 
p=0.00003).  26 
 6  
None of 23 patients with SM experienced sICH, systemic bleeding or death. At 1 
discharge, 16 (70%) patients were without any neurological symptoms (NIHSS score 0, 2 
mRS score 0), whereas 7 (30%) patients had persisting residual deficits due to the 3 
condition that caused the acute neurological deficit but without any worsening of the 4 
symptoms after IVT. 5 
 6 
Literature Review 7 
Our literature search resulted in 13 reports (10 cohort studies, 3 case reports) fulfilling 8 
the predefined criteria [8-20]. These included a total of 209 patients with SM (mean 9 
frequency 6%) treated with IVT, 200 (96%) of them within the 3h treatment time 10 
window. Symptomatic ICH was reported in 1 of 209 (0.5%) cases [19]. 11 
 12 
DISCUSSION 13 
Although time constraints in the diagnostic workup and administration of IVT for 14 
patients with suspected IS are prone to misdiagnosis, this study demonstrates that IVT 15 
carries minimal risks of serious adverse events in these patients. In our cohort, 7% of 16 
thrombolyzed patients had a misdiagnosis of ischemic stroke. Similar to our findings, 17 
Giraldo et al. reported that 9 of 89 (10%) patients undergoing IVT within 4.5 hours were 18 
misdiagnosed as IS. For the 3h treatment time window, SM rates of 1 -13% (mean 6%) 19 
have been reported [8, 11-14, 16, 18, 20]. The wide range of SM rates in these studies 20 
probably relates to several factors such as study size, definition of SM, treatment 21 
protocol and experience of respective center. Patients with SM underwent IVT later 22 
than patients with IS in this series. In the absence of data about door-to-needle time, 23 
we do not know whether this difference was caused by a pre-hospital or an in-hospital 24 
delay, hence, whether this delay was related to the uncertainty of the patient or 25 
primary/emergency physician to send the patient to the hospital or a longer diagnostic 26 
 7  
work-up in the hospital. Our data suggest that age and presence of vascular risk factors 1 
do not predict SM. In fact, epileptic seizures mimicking IS typically occurred in older 2 
patients with higher vascular risk profiles. In contrast, young patients with IS often have 3 
no cardiovascular risk factors and stroke of non-atherosclerotic etiology, e.g. due to 4 
cervical artery dissection [21].  5 
The main strength of our study is the comparison of NIHSS subscores in patients with 6 
SM and IS. Our results show that the presence of oculomotor disturbance, hemianopia, 7 
facial palsy, dysarthria or hemineglect strongly suggest IS. In contrast, global aphasia 8 
in the absence of hemiparesis should raise the suspicion of SM, which is in line with the 9 
findings of Winkler et al. [12]. It is noteworthy that the frequency of common stroke 10 
symptoms such as aphasia, leg paresis or sensory disturbances were similarly 11 
distributed in the 2 groups, whereas arm paresis was slightly more often observed in IS. 12 
However, the latter finding may be coincidental in view of the small sample size and 13 
marginal statistical difference. 14 
Epileptic seizure was the most common cause for SM in our cohort, followed by 15 
migraine and conversion disorder. These findings are in line with the literature [3, 14, 16 
20]. Among less frequent etiologies, multiple sclerosis, hypoglycemia and systemic 17 
infection mimicked IS in our study. Perfusion CT, which has a broad availability and 18 
short processing time, may be an alternative diagnostic tool to detect epileptic seizures 19 
mimicking acute IS: while cerebral regional hyperperfusion has been reported to be 20 
characteristic for nonconvulsive status epilepticus [22, 23], focal hypoperfusion in 21 
atypical vascular distributions was reported for post-ictal neurological deficits [24]. CT 22 
angiography was performed in 22 of 23 patients with SM and showed normal findings. 23 
Retrospectively, the obvious discrepancy between patent cerebral arteries in CTA and 24 
high NIHSS scores (e.g. patients Nr. 10, 12, 20, 23) should suggest a SM. 25 
Furthermore, neurologists should consider the CT findings prior to thrombolysis 26 
 8  
carefully. Reviewing the CT images, 3 patients (Nr. 1, 11 and 18) had subtle, but visible 1 
lesions that retrospectively should have raised suspicion of a SM. In patient Nr. 18, 2 
treatment with alteplase was stopped 15 min after bolus application when a subdural 3 
hematoma was detected after reviewing the CT images.  4 
 5 
To assess the risk of adverse events after IVT, our meta-analysis includes 232 patients 6 
with SM treated with IVT. None of the patients died. Grimm et al. reported 1 patient 7 
(case report) experiencing sICH after IVT due to underlying glioblastoma multiforme 8 
[10]. In 2 other studies, 1 patient suffered from gastrointestinal hemorrhage and 2 9 
patients from cervical epidural hemorrhage [16, 17]. In one of these patients, it is 10 
unclear whether spinal hematoma was pre-existing, hence, the cause of stroke-like 11 
symptoms and not a complication of IVT [16]. In the other case, the hematoma may 12 
also have existed before IVT as suggested by the clinical presentation with acute 13 
shoulder pain and face-sparing hemiparesis [17]. Though, our data suggest that the 14 
risk of hemorrhage seems to be low, a direct comparison of the bleeding risk 15 
attributable to IVT in SM versus in IS in large dataset is warranted. Furthermore, 16 
caution is needed when interpreting these findings as the low complication risk may be 17 
valid only for experienced stroke centers.  18 
Some limitations should be considered in this study. The sample size of the SM group 19 
was small, thus the analysis is prone to type II errors. We therefore included a 20 
metaanalysis of published SM series to better ascertain the risk of hemorrhage in 21 
patients with SM after IVT – with the caveat that the definition of SM and sICH was not 22 
identical in all studies. Further support for low sICH risks in patients without IS is 23 
derived from studies that assessed intravenous r-tPA for acute myocardial infarction. 24 
The sICH risk in these patients is less than 1% despite the addition of intravenous 25 
heparin to the treatment protocol [25]. Another limitation is the use of the NIHSS for 26 
 9  
assessing the neurological outcome at discharge from the hospital. While the NIHSS is 1 
applicable to IS, its value for assessing the symptoms of conditions other than stroke is 2 
limited. 3 
In conclusion, our study suggests that the pattern of clinical deficits measured by 4 
NIHSS differs between SM and IS, whereas common stroke predictors such as age 5 
and vascular risk factors were similarly distributed in both groups. 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
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Table 1. Comparison of baseline characteristics in thrombolysed patients with stroke 1 
mimic (n=23) or ischemic stroke (n=303). 2 
 3 
 Stroke mimic, n/N (%) Ischemic stroke, n/N (%) p 
Age, mean years ± SD 63.0 ± 19.2 69.9 ± 14.0 0.19* 
Male gender 13/23 (56.5%) 202/303 (66.7%) 0.36 
Arterial hypertension 13/23 (56.5%) 209/296 (70.6%) 0.16 
Diabetes mellitus 4/21 (19.0%) 41/262 (15.6%) 0.76 
Current smoking 7/22 (31.9%) 60/270 (22.2%) 0.30 
History of ischemic stroke 2/22 (9.1%) 58/288 (20.1%) 0.27 
Coronary artery disease 2/22 (9.1%) 59/296 (19.9%) 0.27 
Mean NIHSS ± SD 6.43 ± 5.21 9.89 ± 6.0 0.003* 
 Mean OTT (min) ± SD 208.3 ± 43.7 156.1 ± 68.0 <0.001* 
 4 
p values from Fisher’s Exact Test, unless otherwise indicated 5 
*Wilcoxon Rank Sum Test 6 
NIHSS indicates National Institutes of Health Stroke Scale, OTT onset to treatment time 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
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Table 2. Characteristics of patients with stroke mimic undergoing intravenous thrombolysis.  
 
N° Gender,  Age (years) Signs at Admission NIHSS 
OTT  
(min)  
Neuroimaging 
at admission 
Radiological finding 
at admission EEG Comorbidities Final Diagnosis 
NIHSS/ 
mRS at 
Discharge 
1 F, 78 Aphasia, confusion 3 190 CT (without contrast agent) 
Subcortical 
hypodense lesion Irritative focus DM 
Glioblastoma with 
symptomatic seizure 4/3* 
2 F, 76 Left hemiparesis 5 150  CT, CTA Meningeoma. Normal CTA Irritative focus 
Meningeoma, 
M. Sjögren  Epileptic seizure 2/1* 
3 M, 78 Aphasia 3 210 CT, CTA Normal CT/CTA - DM, HT,  DL, CAD Hypoglycemia 0/0 
4 M, 34 Right hemiparesis 6 230 CT, CTA Normal CT/CTA - M. Hodgkin Multiple sclerosis 6/2* 
5 M, 41 Speech arrest, left sensory hemisyndrome 5 220 CT, CTA Normal CT/CTA Epileptic focus smoking Epileptic seizure 0/0 
6 F, 86 Aphasia 5 235 CT, CTA Meningeoma. Normal CTA Irritative focus 
Meningeoma, 
HT, CAD Epileptic seizure 0/0 
7 M, 76 Left sensory hemisyndrome 3 260 CT, CTA 
Chronic infarct. 
Normal CTA 
Temporal 
focal slowing  
Prior stroke, HT, 
smoking Epileptic seizure 0/0 
8 M, 30 Aphasia 2 240 CT, CTA, PCT Normal CT/CTA/PCT - MwA, smoking  Migraine with aura 0/0 
9 F, 55 Vertigo, right sensory hemisyndrome 4 210 CT, CTA Normal CT/CTA Normal HT, DL Conversion disorder 2/2* 
10 F, 59 Nausea, right hemisyndrome 9 225 CT, CTA Normal CT/CTA 
Temporal 
focal slowing - Epileptic seizure 0/0 
 12  
11 F, 83 Aphasia, confusion headache 2 225 CT, CTA 
Sinus obliteration. 
Normal CTA Normal HT 
Sinusitis with 
systemic infection 0/0 
12 M, 46 Aphasia, tetraplegia 19 110 CT, CTA Normal CT/CTA Normal Depression, MwA, HT, DL Conversion disorder 0/0 
13 F, 74 Aphasia 3 185 CT, CTA Normal CT/CTA - DM, HT, DL Epileptic seizure 0/0 
14 M, 75 Speech arrest, right hemiparesis 7 255 CT, CTA 
Chronic infarct. 
Normal CTA 
Temporal 
focal slowing  DL, prior stroke  Epileptic seizure 0/0 
15 M, 77 Aphasia, facial paresis 8 240 CT, CTA Normal CT/CTA - DL, DM Epileptic seizure 0/0 
16 F, 77 Aphasia, facial paresis 6 170 CT, CTA Normal CT/CTA Irritative focus  DM, HT Epileptic seizure 0/0 
17 M, 27 Left sensory hemisyndrome 5 180 CT, CTA Normal CT/CTA Normal smoking Migraine with aura 0/0 
18 M, 75 Right hemiparesis 6 150 CT, CTA Subdural hematoma. Normal CTA Irritative focus 
HT, DL, 
smoking, CAD 
Subdural hematoma 
with symptomatic 
seizure 
2/1* 
19 F, 76 Left hemiparesis 6 135 CT, CTA Normal CT/CTA Normal RLS, HT, dizziness Conversion disorder 1/1 
20 M, 71 Aphasia, tetraplegia 23 270 CT, CTA Leukoaraiosis.Chronic infarct. Normal CTA 
Status 
epilepticus 
HT, DM, AF, 
schizophrenia Status epilepticus 5/2* 
21 F, 66 Aphasia 3 195 CT, CTA Chronic infarct. Normal CTA Irritative focus HT Epileptic seizure 0/0 
22 M, 27 Left sensory hemisyndrome 3 265 CT, CTA Normal CT/CTA Normal MwA Migraine with aura 0/0 
23 M, 62 Aphasia, right hemiparesis 12 240 CT, CTA Normal CT/CTA Irritative focus  HT, smoking 
Glioblastoma with 
symptomatic seizure 0/0 
 13  
NIHSS indicates National Institutes of Health Stroke Scale, OTT onset to treatment time, EEG electroencephalography, mRS modified Rankin scale, DWI diffusion 
weighted imaging, DM diabetes mellitus, HT arterial hypertension, DL dyslipidemia, CAD coronary artery disease, MwA migraine with aura, RLS restless legs 
syndrome, AF atrial fibrillation, CT computed tomography, CTA computed tomography angiography , PCT perfusion computed tomography. 
* due to comorbidity
14 
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